Stockreport

Truist Reiterates Buy Rating for Viridian Therapeutics (VRDN) [Yahoo! Finance]

Viridian Therapeutics, Inc.  (VRDN) 
PDF On April 21, Truist reduced the price target on Viridian Therapeutics Inc. (NASDAQ:VRDN) from $36 to $33 while maintaining a Buy rating on the stock. Despite the downwa [Read more]